BACKGROUND/AIMS: Human serum paraoxonase1 (PON1), a high-density lipoprotein-associated enzyme, prevents oxidative modification of low-density lipoprotein and, thus, arrests the development of atheroma formation, whose major consequence is the development of coronary artery disease (CAD). A single-nucleotide polymorphism (SNP) Q192R in the coding region at pon1 locus is a determinant of PON1 activity. The relationship between PON1 activity and vascular disease may be influenced by the relationship of PON1 activity or PON1 SNP genotype to lipid and apolipoprotein (Apo) levels. The aim of the study is to ascertain the prevalence of PON1 Q192R polymorphism in male and female subjects with and without CAD along with its influence on ApoA-I and ApoB levels in Asian Indians. METHODS: Determination of genotypes was carried out in 249 diagnosed CAD cases and in 243 age-, gender-matched asymptomatic controls by polymerase chain reaction-restriction fragment length polymorphism. Fasting plasma Apo-levels were estimated by immunoturbidimetric assay. RESULTS: The genotype frequencies did not differ markedly between the overall CAD and control groups and in male and female subjects, suggesting a lack of any genotype-CAD correlation. ApoB levels were found to be higher in female patients carrying RR when compared with QQ genotypes (p=0.03) with no effect on controls. This may be attributed to the postmenopausal state of the women. CONCLUSION: PON1 Q192R can be used as the DNA marker test to evaluate the risk of CAD in postmenopausal Indian women with high ApoB.
BACKGROUND/AIMS: Human serum paraoxonase1 (PON1), a high-density lipoprotein-associated enzyme, prevents oxidative modification of low-density lipoprotein and, thus, arrests the development of atheroma formation, whose major consequence is the development of coronary artery disease (CAD). A single-nucleotide polymorphism (SNP) Q192R in the coding region at pon1 locus is a determinant of PON1 activity. The relationship between PON1 activity and vascular disease may be influenced by the relationship of PON1 activity or PON1 SNP genotype to lipid and apolipoprotein (Apo) levels. The aim of the study is to ascertain the prevalence of PON1Q192R polymorphism in male and female subjects with and without CAD along with its influence on ApoA-I and ApoB levels in Asian Indians. METHODS: Determination of genotypes was carried out in 249 diagnosed CAD cases and in 243 age-, gender-matched asymptomatic controls by polymerase chain reaction-restriction fragment length polymorphism. Fasting plasma Apo-levels were estimated by immunoturbidimetric assay. RESULTS: The genotype frequencies did not differ markedly between the overall CAD and control groups and in male and female subjects, suggesting a lack of any genotype-CAD correlation. ApoB levels were found to be higher in female patients carrying RR when compared with QQ genotypes (p=0.03) with no effect on controls. This may be attributed to the postmenopausal state of the women. CONCLUSION:PON1Q192R can be used as the DNA marker test to evaluate the risk of CAD in postmenopausal Indian women with high ApoB.
Authors: N A Shabana; Sana Ashiq; Anam Ijaz; Fizah Khalid; Istabsar Ul Saadat; Kahkashan Khan; Sumbal Sarwar; Saleem Ullah Shahid Journal: Lipids Health Dis Date: 2018-09-27 Impact factor: 3.876